Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease
Authors:
- Rana T. AlhashimiRARana T. Alhashimi
- Mohini S. GhatgeMGMohini S. Ghatge
- Akua K. DonkorADAkua K. Donkor
- Tanvi M. DeshpandeTDTanvi M. Deshpande
- Nancy AnabaraonyeNANancy Anabaraonye
- Dina AlramadhaniDADina Alramadhani
- Richmond Danso-DanquahRDRichmond Danso-Danquah
- Boshi HuangBHBoshi Huang
- Yan ZhangYZYan Zhang
- Faik N. MusayevFMFaik N. Musayev
- Osheiza AbdulmalikOAOsheiza Abdulmalik
- Martin K. SafoMartin K. Safo
Open Access
- 12 May 2022
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 12 (5) , 696
Abstract
5-hydroxyfurfural (5HMF), an allosteric effector of hemoglobin (Hb) with an ability to increase Hb affinity for oxygen has been studied extensively for its antisickling effect in vitro and in vivo, and in humans for the treatment of sickle cell disease (SCD). One of the downstream pathophysiologies of SCD is nitric oxide (NO) deficiency, therefore increasing NO (bio)availability is known to mitigate the severity of SCD symptoms. We report the synthesis of an NO-releasing prodrug of 5HMF (5HMF-NO), which in vivo, is expected to be bio-transformed into 5HMF and NO, with concomitant therapeutic activities. In vitro studies showed that when incubated with whole blood, 5HMF-NO releases NO, as anticipated. When incubated with sickle blood, 5HMF-NO formed Schiff base adduct with Hb, increased Hb affinity for oxygen, and prevented hypoxia-induced erythrocyte sickling, which at 1 mM concentration were 16%, 10% and 27%, respectively, compared to 21%, 18% and 21% for 5HMF. Crystal structures of 5HMF-NO with Hb showed 5HMF-NO bound to unliganded (deoxygenated) Hb, while the hydrolyzed product, 5HMF bound to liganded (carbonmonoxy-ligated) Hb. Our findings from this proof-of-concept study suggest that the incorporation of NO donor group to 5HMF and analogous molecules could be a novel beneficial strategy to treat SCD and warrants further detailed in vivo studies.Keywords
Funding Information
- NIH/NIMHD (R01MD009124, R61HL156158, S10OD021756)
- NIH/NIMHD (R01MD009124, R61HL156158, S10OD021756)
- NIH Shared Instrumentation (R01MD009124, R61HL156158, S10OD021756)
- Virginia General Assembly Higher Education Equipment Trust Fund (HEETF) (R01MD009124, R61HL156158, S10OD021756)
This publication has 62 references indexed in Scilit:
- Graphical tools for macromolecular crystallography inPHENIXJournal of Applied Crystallography, 2012
- Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillinActa Crystallographica Section D Structural Biology, 2011
- The Phenix software for automated determination of macromolecular structuresMethods, 2011
- Exogenous nitric oxide prevents cardiovascular collapse during hemorrhagic shockResuscitation, 2011
- Overview of theCCP4 suite and current developmentsActa Crystallographica Section D Structural Biology, 2011
- Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain CrisisJAMA, 2011
- Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxideAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Vascular nitric oxide: formation and functionJournal of Blood Medicine, 2010
- PATHOPHISIOLOGY OF SICKLE CELL DISEASE AND NEW DRUGS FOR THE TREATMENTMediterranean Journal of Hematology and Infectious Diseases, 2009
- Nitric Oxide–Releasing DrugsAnnual Review of Pharmacology and Toxicology, 2003